The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Adalimumab Drug Market Research Report 2025
Synopsis
Adalimumab, sold under the brand name Humira, among others, is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis.[23][24][25] It is administered by injection under the skin.
The global Adalimumab Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Adalimumab Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab Drug.
Report Scope
The Adalimumab Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Adalimumab Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adalimumab Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cambridge Antibody Technology
BASF
AbbVie
MABURA
Exemptia
Amgen
Sandoz
Boehringer Ingelheim
Mylan
Biogen
Segment by Type
Adalimumab
Adalimumab Biosimilar
Segment by Application
Adult
Children
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Adalimumab Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Adalimumab, sold under the brand name Humira, among others, is a monoclonal antibody used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis.[23][24][25] It is administered by injection under the skin.
The global Adalimumab Drug market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Adalimumab Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adalimumab Drug.
Report Scope
The Adalimumab Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Adalimumab Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Adalimumab Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Cambridge Antibody Technology
BASF
AbbVie
MABURA
Exemptia
Amgen
Sandoz
Boehringer Ingelheim
Mylan
Biogen
Segment by Type
Adalimumab
Adalimumab Biosimilar
Segment by Application
Adult
Children
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Adalimumab Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Adalimumab Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Adalimumab
1.2.3 Adalimumab Biosimilar
1.3 Market by Application
1.3.1 Global Adalimumab Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Adult
1.3.3 Children
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Adalimumab Drug Market Perspective (2019-2030)
2.2 Adalimumab Drug Growth Trends by Region
2.2.1 Global Adalimumab Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Adalimumab Drug Historic Market Size by Region (2019-2024)
2.2.3 Adalimumab Drug Forecasted Market Size by Region (2025-2030)
2.3 Adalimumab Drug Market Dynamics
2.3.1 Adalimumab Drug Industry Trends
2.3.2 Adalimumab Drug Market Drivers
2.3.3 Adalimumab Drug Market Challenges
2.3.4 Adalimumab Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Adalimumab Drug Players by Revenue
3.1.1 Global Top Adalimumab Drug Players by Revenue (2019-2024)
3.1.2 Global Adalimumab Drug Revenue Market Share by Players (2019-2024)
3.2 Global Adalimumab Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Adalimumab Drug Revenue
3.4 Global Adalimumab Drug Market Concentration Ratio
3.4.1 Global Adalimumab Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Adalimumab Drug Revenue in 2023
3.5 Adalimumab Drug Key Players Head office and Area Served
3.6 Key Players Adalimumab Drug Product Solution and Service
3.7 Date of Enter into Adalimumab Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Adalimumab Drug Breakdown Data by Type
4.1 Global Adalimumab Drug Historic Market Size by Type (2019-2024)
4.2 Global Adalimumab Drug Forecasted Market Size by Type (2025-2030)
5 Adalimumab Drug Breakdown Data by Application
5.1 Global Adalimumab Drug Historic Market Size by Application (2019-2024)
5.2 Global Adalimumab Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Adalimumab Drug Market Size (2019-2030)
6.2 North America Adalimumab Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Adalimumab Drug Market Size by Country (2019-2024)
6.4 North America Adalimumab Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Adalimumab Drug Market Size (2019-2030)
7.2 Europe Adalimumab Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Adalimumab Drug Market Size by Country (2019-2024)
7.4 Europe Adalimumab Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Adalimumab Drug Market Size (2019-2030)
8.2 Asia-Pacific Adalimumab Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Adalimumab Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Adalimumab Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Adalimumab Drug Market Size (2019-2030)
9.2 Latin America Adalimumab Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Adalimumab Drug Market Size by Country (2019-2024)
9.4 Latin America Adalimumab Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Adalimumab Drug Market Size (2019-2030)
10.2 Middle East & Africa Adalimumab Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Adalimumab Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Adalimumab Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Cambridge Antibody Technology
11.1.1 Cambridge Antibody Technology Company Detail
11.1.2 Cambridge Antibody Technology Business Overview
11.1.3 Cambridge Antibody Technology Adalimumab Drug Introduction
11.1.4 Cambridge Antibody Technology Revenue in Adalimumab Drug Business (2019-2024)
11.1.5 Cambridge Antibody Technology Recent Development
11.2 BASF
11.2.1 BASF Company Detail
11.2.2 BASF Business Overview
11.2.3 BASF Adalimumab Drug Introduction
11.2.4 BASF Revenue in Adalimumab Drug Business (2019-2024)
11.2.5 BASF Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Detail
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Adalimumab Drug Introduction
11.3.4 AbbVie Revenue in Adalimumab Drug Business (2019-2024)
11.3.5 AbbVie Recent Development
11.4 MABURA
11.4.1 MABURA Company Detail
11.4.2 MABURA Business Overview
11.4.3 MABURA Adalimumab Drug Introduction
11.4.4 MABURA Revenue in Adalimumab Drug Business (2019-2024)
11.4.5 MABURA Recent Development
11.5 Exemptia
11.5.1 Exemptia Company Detail
11.5.2 Exemptia Business Overview
11.5.3 Exemptia Adalimumab Drug Introduction
11.5.4 Exemptia Revenue in Adalimumab Drug Business (2019-2024)
11.5.5 Exemptia Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Adalimumab Drug Introduction
11.6.4 Amgen Revenue in Adalimumab Drug Business (2019-2024)
11.6.5 Amgen Recent Development
11.7 Sandoz
11.7.1 Sandoz Company Detail
11.7.2 Sandoz Business Overview
11.7.3 Sandoz Adalimumab Drug Introduction
11.7.4 Sandoz Revenue in Adalimumab Drug Business (2019-2024)
11.7.5 Sandoz Recent Development
11.8 Boehringer Ingelheim
11.8.1 Boehringer Ingelheim Company Detail
11.8.2 Boehringer Ingelheim Business Overview
11.8.3 Boehringer Ingelheim Adalimumab Drug Introduction
11.8.4 Boehringer Ingelheim Revenue in Adalimumab Drug Business (2019-2024)
11.8.5 Boehringer Ingelheim Recent Development
11.9 Mylan
11.9.1 Mylan Company Detail
11.9.2 Mylan Business Overview
11.9.3 Mylan Adalimumab Drug Introduction
11.9.4 Mylan Revenue in Adalimumab Drug Business (2019-2024)
11.9.5 Mylan Recent Development
11.10 Biogen
11.10.1 Biogen Company Detail
11.10.2 Biogen Business Overview
11.10.3 Biogen Adalimumab Drug Introduction
11.10.4 Biogen Revenue in Adalimumab Drug Business (2019-2024)
11.10.5 Biogen Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Adalimumab Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Adalimumab
Table 3. Key Players of Adalimumab Biosimilar
Table 4. Global Adalimumab Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Adalimumab Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Adalimumab Drug Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Adalimumab Drug Market Share by Region (2019-2024)
Table 8. Global Adalimumab Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Adalimumab Drug Market Share by Region (2025-2030)
Table 10. Adalimumab Drug Market Trends
Table 11. Adalimumab Drug Market Drivers
Table 12. Adalimumab Drug Market Challenges
Table 13. Adalimumab Drug Market Restraints
Table 14. Global Adalimumab Drug Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Adalimumab Drug Market Share by Players (2019-2024)
Table 16. Global Top Adalimumab Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab Drug as of 2023)
Table 17. Ranking of Global Top Adalimumab Drug Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Adalimumab Drug Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Adalimumab Drug Product Solution and Service
Table 21. Date of Enter into Adalimumab Drug Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Adalimumab Drug Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Adalimumab Drug Revenue Market Share by Type (2019-2024)
Table 25. Global Adalimumab Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Adalimumab Drug Revenue Market Share by Type (2025-2030)
Table 27. Global Adalimumab Drug Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Adalimumab Drug Revenue Market Share by Application (2019-2024)
Table 29. Global Adalimumab Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Adalimumab Drug Revenue Market Share by Application (2025-2030)
Table 31. North America Adalimumab Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Adalimumab Drug Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Adalimumab Drug Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Adalimumab Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Adalimumab Drug Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Adalimumab Drug Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Adalimumab Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Adalimumab Drug Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Adalimumab Drug Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Adalimumab Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Adalimumab Drug Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Adalimumab Drug Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Adalimumab Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Adalimumab Drug Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Adalimumab Drug Market Size by Country (2025-2030) & (US$ Million)
Table 46. Cambridge Antibody Technology Company Detail
Table 47. Cambridge Antibody Technology Business Overview
Table 48. Cambridge Antibody Technology Adalimumab Drug Product
Table 49. Cambridge Antibody Technology Revenue in Adalimumab Drug Business (2019-2024) & (US$ Million)
Table 50. Cambridge Antibody Technology Recent Development
Table 51. BASF Company Detail
Table 52. BASF Business Overview
Table 53. BASF Adalimumab Drug Product
Table 54. BASF Revenue in Adalimumab Drug Business (2019-2024) & (US$ Million)
Table 55. BASF Recent Development
Table 56. AbbVie Company Detail
Table 57. AbbVie Business Overview
Table 58. AbbVie Adalimumab Drug Product
Table 59. AbbVie Revenue in Adalimumab Drug Business (2019-2024) & (US$ Million)
Table 60. AbbVie Recent Development
Table 61. MABURA Company Detail
Table 62. MABURA Business Overview
Table 63. MABURA Adalimumab Drug Product
Table 64. MABURA Revenue in Adalimumab Drug Business (2019-2024) & (US$ Million)
Table 65. MABURA Recent Development
Table 66. Exemptia Company Detail
Table 67. Exemptia Business Overview
Table 68. Exemptia Adalimumab Drug Product
Table 69. Exemptia Revenue in Adalimumab Drug Business (2019-2024) & (US$ Million)
Table 70. Exemptia Recent Development
Table 71. Amgen Company Detail
Table 72. Amgen Business Overview
Table 73. Amgen Adalimumab Drug Product
Table 74. Amgen Revenue in Adalimumab Drug Business (2019-2024) & (US$ Million)
Table 75. Amgen Recent Development
Table 76. Sandoz Company Detail
Table 77. Sandoz Business Overview
Table 78. Sandoz Adalimumab Drug Product
Table 79. Sandoz Revenue in Adalimumab Drug Business (2019-2024) & (US$ Million)
Table 80. Sandoz Recent Development
Table 81. Boehringer Ingelheim Company Detail
Table 82. Boehringer Ingelheim Business Overview
Table 83. Boehringer Ingelheim Adalimumab Drug Product
Table 84. Boehringer Ingelheim Revenue in Adalimumab Drug Business (2019-2024) & (US$ Million)
Table 85. Boehringer Ingelheim Recent Development
Table 86. Mylan Company Detail
Table 87. Mylan Business Overview
Table 88. Mylan Adalimumab Drug Product
Table 89. Mylan Revenue in Adalimumab Drug Business (2019-2024) & (US$ Million)
Table 90. Mylan Recent Development
Table 91. Biogen Company Detail
Table 92. Biogen Business Overview
Table 93. Biogen Adalimumab Drug Product
Table 94. Biogen Revenue in Adalimumab Drug Business (2019-2024) & (US$ Million)
Table 95. Biogen Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Adalimumab Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Adalimumab Drug Market Share by Type: 2023 VS 2030
Figure 3. Adalimumab Features
Figure 4. Adalimumab Biosimilar Features
Figure 5. Global Adalimumab Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Adalimumab Drug Market Share by Application: 2023 VS 2030
Figure 7. Adult Case Studies
Figure 8. Children Case Studies
Figure 9. Adalimumab Drug Report Years Considered
Figure 10. Global Adalimumab Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 11. Global Adalimumab Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Adalimumab Drug Market Share by Region: 2023 VS 2030
Figure 13. Global Adalimumab Drug Market Share by Players in 2023
Figure 14. Global Top Adalimumab Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab Drug as of 2023)
Figure 15. The Top 10 and 5 Players Market Share by Adalimumab Drug Revenue in 2023
Figure 16. North America Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 17. North America Adalimumab Drug Market Share by Country (2019-2030)
Figure 18. United States Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. Canada Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Europe Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Adalimumab Drug Market Share by Country (2019-2030)
Figure 22. Germany Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. France Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. U.K. Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Italy Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Russia Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Nordic Countries Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Asia-Pacific Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Adalimumab Drug Market Share by Region (2019-2030)
Figure 30. China Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Japan Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. South Korea Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Southeast Asia Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. India Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Australia Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Latin America Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Adalimumab Drug Market Share by Country (2019-2030)
Figure 38. Mexico Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Brazil Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Adalimumab Drug Market Share by Country (2019-2030)
Figure 42. Turkey Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Saudi Arabia Adalimumab Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Cambridge Antibody Technology Revenue Growth Rate in Adalimumab Drug Business (2019-2024)
Figure 45. BASF Revenue Growth Rate in Adalimumab Drug Business (2019-2024)
Figure 46. AbbVie Revenue Growth Rate in Adalimumab Drug Business (2019-2024)
Figure 47. MABURA Revenue Growth Rate in Adalimumab Drug Business (2019-2024)
Figure 48. Exemptia Revenue Growth Rate in Adalimumab Drug Business (2019-2024)
Figure 49. Amgen Revenue Growth Rate in Adalimumab Drug Business (2019-2024)
Figure 50. Sandoz Revenue Growth Rate in Adalimumab Drug Business (2019-2024)
Figure 51. Boehringer Ingelheim Revenue Growth Rate in Adalimumab Drug Business (2019-2024)
Figure 52. Mylan Revenue Growth Rate in Adalimumab Drug Business (2019-2024)
Figure 53. Biogen Revenue Growth Rate in Adalimumab Drug Business (2019-2024)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
